Levels of Care: Defining Best Supportive Care in Elderly Patients with Acute Myeloid Leukemia
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
This article reviews published data on best supportive care (BSC) in older patients with acute myeloid leukemia (AML) and proposes improvements in defining this critical aspect of treatment. A clinical challenge is to prospectively identify patients who could benefit from existing therapies and to optimize their treatment tolerance by improving BSC. Advanced age and poor performance status consistently emerge as reliable indicators of poor outcome in older AML patients and have historically been the most important variables used to stratify treatment. Performance status is notoriously difficult to assess, and a “snapshot” view at the time of initial presentation can be misleading. Comorbidity scales may be a better predictor of outcome, but studies looking at their effectiveness are variable. New methods are needed to stratify patients. Although the prognosis of older AML patients is generally dismal, selected patients benefit from treatment and can have prolonged survival. Because it has never been shown that BSC as a sole therapeutic approach is kinder, less expensive, or better for older AML patients, it should be reserved for select clinical situations.
- The NCCN Clinical Practice Guidelines in Oncology™ Acute Myeloid Leukemia (Version 2.2010). Available at www.nccn.org.
- Roboz GJ: Treatment of acute myeloid leukemia in older patients. Expert Rev Anticancer Ther 2007, 7(3):285–295. CrossRef
- Appelbaum FR, Gundacker H, Head DR, et al.: Age and acute myeloid leukemia. Blood 2006, 107(9):3481–3485. CrossRef
- • Fenaux P, Mufti GJ, Hellström-Lindberg E, et al.: Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010, 28(4):562–569. This paper highlights that treatment with 5-azacitidine of older AML patients who have a low bone marrow blast count can prolong overall survival when compared with conventional care regimens including induction chemotherapy, low-dose ara C, and BSC.
- Feldman EJ, Ritchie EK, Gergis U, et al.: Evaluation of alternative “low intensity” regimens in elderly adults with acute myeloid leukemia (AML) [abstract]. Blood 2009, 114(22):Abstract 2066.
- Sekeres MA, Stone RM, Zahrieh D, et al.: Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 2004, 18(4):809–816. CrossRef
- Menzin J, Lang K, Earle C, et al.: The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002, 162(14):1597–1603. CrossRef
- Lowenberg B, Zittoun R, Kerkhofs H, et al.: On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol, 1989, 7(9):1268–1274.
- Burnett AK, Milligan D, Prentice AG, et al.: A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007, 109(6):1114–1124. CrossRef
- Harousseau JL, Martinelli G, Jedizejczak WW, et al.: A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood 2009, 114(6):1166–1173. CrossRef
- Kantarjian H, O’Brien S, Cortes J, et al.: Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006, 106(5):1090–1098. CrossRef
- Fried LP, Kronmal RA, Newman AB, et al.: Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA 1998, 279(8):585–592. CrossRef
- Fried LP, Tangen CM, Walston J, et al.: Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001, 56(3):M146–M156.
- Giles FJ, Borthakur G, Ravandi F, et al.: The Haematopoietic Cell Transplantation Comorbidity Index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 2007, 136(4):624–627. CrossRef
- Breccia M, Frustaci AM, Cannella L, et al.: Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients. Hematol Oncol 2009, 27(3):148–153. CrossRef
- Harb AJ, Tan W, Wilding GE, et al.: Treating octogenarian and nonagenarian acute myeloid leukemia patients—predictive prognostic models. Cancer 2009, 115(11):2472–2481. CrossRef
- Meyerhardt JA, Catalano PJ, Haller DG, et al.: Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 2003, 21(3):433–440. CrossRef
- Hammarsten J, Hogstedt B: Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 2005, 41(18):2887–2895. CrossRef
- Goodwin PJ, Ennis M, Prichard KI, et al.: Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002, 20(1):42–51. CrossRef
- Pavelka JC, Brown RS, Karlan BY, et al.: Effect of obesity on survival in epithelial ovarian cancer. Cancer 2006, 107(7):1520–1524. CrossRef
- Stuck AE, Siu AL, Wieland GD, et al.: Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet 1993, 342(8878):1032–1036. CrossRef
- Leith CP, Kopecky KJ, Godwin J, et al.: Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997, 89(9):3323–3329.
- • Rao AV, Valk PJ, Metzeler KH, et al.: Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. J Clin Oncol 2009, 27(33):5580–5586. This paper suggests that treatment with hypomethylating agents in older adults with poor prognostic features may produce a better outcome than standard induction chemotherapy.
- Farag SS, Archer KJ, Mrozek K, et al.: Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006, 108(1):63–73. CrossRef
- Ravandi F, Issa JP, Garcia-Manero G, et al.: Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer 2009, 115(24):5746–5751. CrossRef
- Estey E, de Lima M, Tibes R, et al.: Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007, 109(4):1395–1400. CrossRef
- Disperati P, Minden MD, Gupta V, et al.: Acute promyelocytic leukemia in patients aged 70 years and over—a single center experience of unselected patients. Leuk Lymphoma 2007, 48(8):1654–1658. CrossRef
- Tallman MS: Treatment of elderly adults with acute promyelocytic leukemia: put the pedal to metal. Leuk Lymphoma 2009, 50(1):12–13. CrossRef
- Prébet T, Boissel N, Reutenauer S, et al.: Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML Intergroup. J Clin Oncol 2009, 27(28):4747–4753. CrossRef
- • Becker H, Marcucci G, Maharry K, et al.: Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol 2010, 28(4):596–604. This paper shows that the molecular marker NPM1 can identify older patients with favorable prognosis, particularly past age 70, and that old age alone should not exclude patients from treatment with induction chemotherapy.
- Heil G, Boissel N, Reutenauer S, et al.: Long-term survival data from a phase 3 study of Filgrastim as an adjunct to chemotherapy in adults with de novo acute myeloid leukemia. Leukemia 2006, 20(3):404–409. CrossRef
- Chaves PH, Ashar B, Guralnik JM, et al.: Looking at the relationship between hemoglobin concentration and prevalent mobility difficulty in older women. Should the criteria currently used to define anemia in older people be reevaluated? J Am Geriatr Soc 2002, 50(7):1257–1264. CrossRef
- Zakai NA, Katz R, Hirsch C, et al.: A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health Study. Arch Intern Med 2005, 165(19):2214–2220. CrossRef
- Chaves PH, Carlson MC, Ferrucci L, et al.: Association between mild anemia and executive function impairment in community-dwelling older women: The Women’s Health and Aging Study II. J Am Geriatr Soc 2006, 54(9):1429–1435. CrossRef
- Luciani A, Jacobsen PB, Extermann M, et al.: Fatigue and functional dependence in older cancer patients. Am J Clin Oncol 2008, 31(5):424–430. CrossRef
- Yancik R: Population aging and cancer: a cross-national concern. Cancer J 2005, 11(6):437–441. CrossRef
- Gardner A, Mattiuzzi G, Faderl S, et al.: Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. J Clin Oncol 2008, 26(35):5684–5688. CrossRef
- Levels of Care: Defining Best Supportive Care in Elderly Patients with Acute Myeloid Leukemia
Current Hematologic Malignancy Reports
Volume 5, Issue 2 , pp 95-100
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Acute myeloid leukemia
- Best supportive care
- Industry Sectors